Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 May;76(5):831-839.
doi: 10.1136/annrheumdis-2016-209831. Epub 2017 Jan 13.

A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate

Josef S Smolen  1 , Sandeep K Agarwal  2 , Elena Ilivanova  3 , Xie Lillian Xu  4 , Ye Miao  5 , Yanli Zhuang  5 , Ivo Nnane  5 , Waldemar Radziszewski  4 , Andrew Greenspan  4 , Anna Beutler  5 , Daniel Baker  5
Affiliations
Clinical Trial

A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate

Josef S Smolen et al. Ann Rheum Dis. 2017 May.

Abstract

Objective: Interleukin (IL)-12 and IL-23 have been implicated in the pathogenesis of rheumatoid arthritis (RA). The safety and efficacy of ustekinumab, a human monoclonal anti-IL-12/23 p40 antibody, and guselkumab, a human monoclonal anti-IL-23 antibody, were evaluated in adults with active RA despite methotrexate (MTX) therapy.

Methods: Patients were randomly assigned (1:1:1:1:1) to receive placebo at weeks 0, 4 and every 8 weeks (n=55), ustekinumab 90 mg at weeks 0, 4 and every 8 weeks (n=55), ustekinumab 90 mg at weeks 0, 4 and every 12 weeks (n=55), guselkumab 50 mg at weeks 0, 4 and every 8 weeks (n=55), or guselkumab 200 mg at weeks 0, 4 and every 8 weeks (n=54) through week 28; all patients continued a stable dose of MTX (10-25 mg/week). The primary end point was the proportion of patients with at least a 20% improvement in the American College of Rheumatology criteria (ACR 20) at week 28. Safety was monitored through week 48.

Results: At week 28, there were no statistically significant differences in the proportions of patients achieving an ACR 20 response between the combined ustekinumab group (53.6%) or the combined guselkumab group (41.3%) compared with placebo (40.0%) (p=0.101 and p=0.877, respectively). Through week 48, the proportions of patients with at least one adverse event (AE) were comparable among the treatment groups. Infections were the most common type of AE.

Conclusions: Treatment with ustekinumab or guselkumab did not significantly reduce the signs and symptoms of RA. No new safety findings were observed with either treatment.

Trial registration number: NCT01645280.

Keywords: Disease Activity; Methotrexate; Rheumatoid Arthritis; Treatment.

PubMed Disclaimer

Conflict of interest statement

Competing interests: JSS has received grants from AbbVie, BMS, Janssen, Lilly, MSD, Pfizer and Roche and has served as a consultant for AbbVie, Amgen, Astra-Zeneca, Astro, BMS, GlaxoSmithKline, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, Samsung, Sanofi-Aventis and UCB. SKA served as a Steering Committee member for Janssen. EI served as a trial investigator for Janssen. XLX, YZ, IN, AG, and DB and YM are employees of Janssen Research & Development, LLC, and own stock in Johnson & Johnson, of which Janssen Research & Development, LLC, is a wholly owned subsidiary. AB and WR were employees of Janssen Research & Development, LLC, at the time this work was performed and own stock in Johnson & Johnson, of which Janssen Research & Development, LLC, is a wholly owned subsidiary. WR is currently employed at Sandoz, Inc., Princeton, NJ.

Figures

Figure 1
Figure 1
Patient disposition through week 28. AE, adverse event; MTX, methotrexate.
Figure 2
Figure 2
Proportions of patients with an ACR20, ACR50 or ACR70 response at week 28. ACR20 response includes all randomised patients. ACR50 and ACR70 responses include patients who received ≥1 dose of study agent. ACR20/50/70, ≥20%/50%/70% improvement in the American College of Rheumatology criteria; MTX, methotrexate.
Figure 3
Figure 3
Mean Clinical Disease Activity Index (CDAI; panel A) and Simplified Disease Activity Index (SDAI; panel B) Scores through week 28. MTX, methotrexate.
See this image and copyright information in PMC

References

    1. Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009;60:2272–83. 10.1002/art.24638 - DOI - PubMed
    1. Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009;68:789–96. 10.1136/ard.2008.099010 - DOI - PMC - PubMed
    1. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675–81. 10.1016/S0140-6736(04)15640-7 - DOI - PubMed
    1. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999;354:1932–9. - PubMed
    1. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478–86. 10.7326/0003-4819-130-6-199903160-00004 - DOI - PubMed

Publication types

MeSH terms

Associated data